- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Brenner tumor.
Displaying page 1 of 1.
EudraCT Number: 2011-005603-32 | Sponsor Protocol Number: K357 | Start Date*: 2012-09-17 | |||||||||||
Sponsor Name:German Cancer Research Center (DKFZ) | |||||||||||||
Full Title: Use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms | |||||||||||||
Medical condition: Early detection of Colorectal neoplasms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011400-33 | Sponsor Protocol Number: MO22224 | Start Date*: 2009-08-12 | |||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or... | |||||||||||||||||||||||
Medical condition: Platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: SE (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) FR (Completed) DK (Completed) NL (Completed) BE (Completed) FI (Completed) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000502-30 | Sponsor Protocol Number: DKFZ-2019-001 | Start Date*: 2020-03-26 | |||||||||||||||||||||
Sponsor Name:German Cancer Research Center (DKFZ) | |||||||||||||||||||||||
Full Title: Personalized Vitamin D Supplementation for Reducing or Preventing Fatigue and Enhancing Quality of Life of Patients with Colorectal Tumor: Randomized Intervention Trial | |||||||||||||||||||||||
Medical condition: Fatigue in patients with colorectal cancer (ICD codes C18-C20 and C21.8) within 12 months after a colorectal cancer therapy (surgery, chemotherapy and/ or radiation) and not optimal vitamin D status | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005975-17 | Sponsor Protocol Number: MO28113 | Start Date*: 2012-08-17 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A two-part, randomized Phase II, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in ... | |||||||||||||
Medical condition: Women with recurrent platinum-resistant or refractory epithelial ovarian cancer and low HER3 mRNA expression. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) IT (Completed) NL (Completed) SE (Completed) BE (Completed) AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001933-38 | Sponsor Protocol Number: ONCX-NAV-G301 | Start Date*: 2021-12-30 | |||||||||||
Sponsor Name:OncXerna Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Multicenter, Open-Label, Randomized Study of Navicixizumab Plus Paclitaxel and Navicixizumab Monotherapy in Comparison to Paclitaxel Monotherapy in Patients with Platinum-Resistant Epithe... | |||||||||||||
Medical condition: Patients With Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004936-72 | Sponsor Protocol Number: WO42178 | Start Date*: 2021-08-25 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE II, OPEN-LABEL, MULTICENTER, PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF BIOMARKER-DRIVEN THERAPIES IN PATIENTS WITH PERSISTENT OR RECURRENT RARE EPITHELIAL OVARIAN TUMORS | ||||||||||||||||||||||||||||||||||||||
Medical condition: Persistent or Recurrent Rare Epithelial Ovarian Tumors | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) BE (Completed) IT (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005181-20 | Sponsor Protocol Number: CEPO906A2303 | Start Date*: 2006-05-19 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/r... | ||
Medical condition: Approximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Favorable prognostic factors include yo... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) ES (Completed) FI (Completed) DK (Completed) HU (Completed) GR (Completed) IT (Completed) IE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
